Braxia Scientific, headed by one of the world’s leading leading depression researchers, aims to treat people with depression and debilitating mental illnesses by revolutionizing global mental healthcare practices and developing the next generation of novel ketamine and psychedelic treatments, and delivery systems, through a growing network of Braxia clinics.
Discover more
Tryp Therapeutics is a pharmaceutical company focused on developing compounds with known activity and/or safety profiles for the treatment of rare diseases and other diseases with high unmet medical needs. Tryp’s psilocybin-for-neuropsychiatric disorders, or PFN™, program is focused on the development of synthetic psilocybin as a new class of drug for the treatment of certain neuropsychiatric-based disorders.
Discover more
We’re on a mission to revolutionize mental healthcare. Cybin is focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.
Discover more
We are integrating psychedelic medicine into mainstream healthcare to enable better mental health for more people through Research, Clinics, and Ecosystems.
Discover more
Gwella makes mushrooms for modern life. Our mission is to build the most accessible and original over the counter portfolio of functional and psychedelic mushroom products that amplify individual and community wellness.
Discover moreJoin over 25,000 investors, academics and operators who receive the latest news on the psychedelic science and healthcare industry. Straight to your inbox once a week.